Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer.

Med (New York, N.Y.) - 13 Jun 2025

Lansbergen Marjolein F, Dings Mark P G, Koster Jan, Labots Mariette, Kerver Emile D, Jochems Anouk, Homs Marjolein Y V, de Vos-Geelen Judith, Hendriks Mathijs P, Tanck Michael W T, Wilmink Johanna W, van Laarhoven Hanneke W M, Bijlsma Maarten F

Abstract excerpt

BACKGROUND: First-line chemotherapy (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin [FOLFIRINOX]) benefits few patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Prognostic markers for treatment-related survival are needed. This study validated the added benefit of whole-genome sequencing (WGS) to transcriptome-based classification in modeling FOLFIRINOX-related survival. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Leucovorin

Share to Oxaliplatin

Share to Pancreatic Neoplasms

Share to Sequence Analysis, RNA

Share to Whole Genome Sequencing

Source

Identifiers

PMID: 39938521
DOI: 10.1016/j.medj.2025.100601

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer.PMID 39938521Read ↗

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trialSemantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.Semantic proximity Read ↗

Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerSemantic proximity Read ↗

Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.Semantic proximity Read ↗

Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic CancerSemantic proximity Read ↗

Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implicationsSemantic proximity Read ↗

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.Semantic proximity Read ↗

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaSemantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read ↗

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.